These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16502804)

  • 21. Oral controlled release preparations.
    García CR; Siqueiros A; Benet LZ
    Pharm Acta Helv; 1978; 53(3-4):99-109. PubMed ID: 360228
    [No Abstract]   [Full Text] [Related]  

  • 22. Application of percolation theory in the study of an extended release Verapamil hydrochloride formulation.
    Gonçalves-Araújo T; Rajabi-Siahboomi AR; Caraballo I
    Int J Pharm; 2008 Sep; 361(1-2):112-7. PubMed ID: 18621491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Release behavior of drugs from various natural gums and polymers.
    Singh A; Sharma PK; Malviya R
    Polim Med; 2011; 41(4):73-80. PubMed ID: 22332328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets.
    Li FQ; Hu JH; Deng JX; Su H; Xu S; Liu JY
    Int J Pharm; 2006 Nov; 324(2):152-7. PubMed ID: 16837152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained-release matrix tablets of metformin hydrochloride in combination with triacetyl-beta-cyclodextrin.
    Corti G; Cirri M; Maestrelli F; Mennini N; Mura P
    Eur J Pharm Biopharm; 2008 Feb; 68(2):303-9. PubMed ID: 17616379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Theophylline loaded gastroretentive floating tablets based on hydrophilic polymers: preparation and in vitro evaluation.
    Khan F; Ibn Razzak SM; Khan ZR; Azad MA; Chowdhury JA; Reza S
    Pak J Pharm Sci; 2009 Apr; 22(2):155-61. PubMed ID: 19339225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mucoadhesive polymeric platforms for controlled drug delivery.
    Andrews GP; Laverty TP; Jones DS
    Eur J Pharm Biopharm; 2009 Mar; 71(3):505-18. PubMed ID: 18984051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and in vitro evaluation of a controlled release formulation to produce wide dose interval morphine tablets.
    Holgado MA; Iruin A; Alvarez-Fuentes J; Fernández-Arévalo M
    Eur J Pharm Biopharm; 2008 Oct; 70(2):544-9. PubMed ID: 18588973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Release of the active agent from matrix tablets with mastix as the base substance].
    Georgarakis M; Georgakopoulos PP
    Pharmazie; 1984 Mar; 39(3):186-7. PubMed ID: 6728892
    [No Abstract]   [Full Text] [Related]  

  • 30. Formulation and optimization of controlled release mucoadhesive tablets of atenolol using response surface methodology.
    Singh B; Chakkal SK; Ahuja N
    AAPS PharmSciTech; 2006 Jan; 7(1):E3. PubMed ID: 16584161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of drug release kinetics from hydroxypropyl methyl cellulose matrix tablets using polyvinyl pyrrolidone.
    Hardy IJ; Windberg-Baarup A; Neri C; Byway PV; Booth SW; Fitzpatrick S
    Int J Pharm; 2007 Jun; 337(1-2):246-53. PubMed ID: 17306477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polysaccharide hydrogels for modified release formulations.
    Coviello T; Matricardi P; Marianecci C; Alhaique F
    J Control Release; 2007 May; 119(1):5-24. PubMed ID: 17382422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral matrix tablet formulations for concomitant controlled release of anti-tubercular drugs: design and in vitro evaluations.
    Hiremath PS; Saha RN
    Int J Pharm; 2008 Oct; 362(1-2):118-25. PubMed ID: 18640251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Relation between the structure of polymers and the controlled release of active ingredients].
    Peppas NA; Gurny R
    Pharm Acta Helv; 1983; 58(1):2-8. PubMed ID: 6338530
    [No Abstract]   [Full Text] [Related]  

  • 35. Citric acid monohydrate as a release-modifying agent in melt extruded matrix tablets.
    Schilling SU; Bruce CD; Shah NH; Malick AW; McGinity JW
    Int J Pharm; 2008 Sep; 361(1-2):158-68. PubMed ID: 18582547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and in vitro/in vivo evaluation of novel nicorandil extended release matrix tablets based on hydrophilic interpolymer complexes and a hydrophobic waxy polymer.
    Abdelbary GA; Tadros MI
    Eur J Pharm Biopharm; 2008 Aug; 69(3):1019-28. PubMed ID: 18295465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of drug release kinetics of shellac-based matrix tablets by in-situ polymerization through annealing process.
    Limmatvapirat S; Limmatvapirat C; Puttipipatkhachorn S; Nunthanid J; Luangtana-anan M; Sriamornsak P
    Eur J Pharm Biopharm; 2008 Aug; 69(3):1004-13. PubMed ID: 18362064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended-release oral drug delivery technologies: monolithic matrix systems.
    Tiwari SB; Rajabi-Siahboomi AR
    Methods Mol Biol; 2008; 437():217-43. PubMed ID: 18369971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compaction properties, drug release kinetics and fronts movement studies from matrices combining mixtures of swellable and inert polymers: effect of HPMC of different viscosity grades.
    Escudero JJ; Ferrero C; Jiménez-Castellanos MR
    Int J Pharm; 2008 Mar; 351(1-2):61-73. PubMed ID: 17996408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and in vitro evaluation of formulations with pH and transit time controlled sigmoidal release profile for colon-specific delivery.
    Asghar LF; Azeemuddin M; Jain V; Chandran S
    Drug Deliv; 2009 May; 16(4):205-13. PubMed ID: 19514981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.